-

Cimeio Therapeutics Announces Poster Presentations at ASH 2023

- CD45 ADC effectively eliminates AML cells in vivo, while CD45 epitope-edited healthy cells were shielded from ADC depletion -

BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cimeio Therapeutics, a biotechnology company that is the leader of the field of epitope editing, today announced the acceptance of two abstracts to be presented at the American Society of Hematology meeting in December 2023 in San Diego.

The first abstract is titled “Hematopoietic Stem Cells Expressing Engineered CD45 Enable a Near Universal Targeted Therapy for Hematologic Diseases.” These data demonstrate that CD45 antibody-drug conjugate (ADC) therapy effectively treated aggressive AML tumors in mouse models. The CD45 ADC therapy was enabled by epitope-edited blood stem cells (HSPCs), which maintain their function but resist depletion by the ADC. This combination therapy could have therapeutic potential in AML and other hematologic malignancies.

The second abstract is titled “Base Edited HSPCs Are Shielded from Targeted CD33 Therapy but Preserve CD33 Expression.” This abstract outlines the development of an edited epitope for CD33, which also resists depletion by paired CD33-directed immunotherapies while maintaining its expression. CD33 represents the fourth target Cimeio has demonstrated it can effectively shield from immunotherapy depletion.

“These data represent important steps in our quest to develop a novel therapy with the potential to cure patients with AML,” said Cimeio CEO Thomas Fuchs. “This work gives us high confidence that our immunotherapies have the potential to transform the treatment of AML and other hematologic malignancies.”

Presentation Details

Title: Hematopoietic Stem Cells Expressing Engineered CD45 Enable a Near Universal Targeted Therapy for Hematologic Diseases
Session Name: 701. Experimental Transplantation: Basic and Translational: Poster II
Session Date: Sunday, December 10, 2023
Presentation Time: 6:00 PM-8:00 PM
Location: San Diego Convention Center Halls G-H

Title: Base Edited HSPCs Are Shielded from Targeted CD33 Therapy but Preserve CD33 Expression
Session Name: 701. Experimental Transplantation: Basic and Translational: Poster II
Session Date: Sunday, December 10, 2023
Presentation Time: 6:00 PM-8:00 PM
Location: San Diego Convention Center Halls G-H

About Cimeio

Cimeio is the leader of the field of epitope editing and is developing a portfolio of Shielded-Cell & Immunotherapy Pairs™ (SCIP), novel immunotherapies which have the potential to transform treatment of hematologic diseases. Cimeio develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in HSCs. These novel epitope edited variants maintain their function but are resistant to depletion when targeted by the paired immunotherapy which has high affinity for the wild-type version of these proteins. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. Shielded Cell and Immunotherapy Pairs and SCIP are trademarks of Cimeio Therapeutics, Inc. For more information, please visit www.cimeio.com.

Contacts

Steve Edelson
sedelson@versantventures.com
415-801-8088

Cimeio Therapeutics


Release Versions

Contacts

Steve Edelson
sedelson@versantventures.com
415-801-8088

More News From Cimeio Therapeutics

Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

BASEL, Switzerland--(BUSINESS WIRE)--Cimeio Therapeutics announced today that it has entered a research collaboration with Kyowa Kirin Co., Ltd. (Kyowa Kirin) to develop a novel therapy for diseases with high unmet need. The partnership combines Cimeio’s proprietary Shielded-Cell & Immunotherapy Pairs™ (SCIP) platform with Kyowa Kirin’s expertise in cellular therapies and underscores both companies’ commitment to using emerging cell and gene therapy technologies to develop new ways to treat...

Cimeio Therapeutics Announces Publication in Nature Demonstrating That CD45 ADC and Shielded HSCs Represent a Potentially Universal Therapy for Blood Cancers

BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cimeio Therapeutics today announced a publication in Nature showing that its CD45 antibody-drug conjugate (ADC) eradicated aggressive leukemic cells in vivo, while hematopoiesis was fully preserved and protected from the ADC via shielded hematopoietic stem cells (HSCs). The findings point to a novel and potentially universal approach to treating blood cancers. CD45 is highly expressed on blood cancers but also on healthy blood cells. This...

Cimeio Therapeutics Presents Data for its CD52 Shielding Variant at ASGCT

BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cimeio Therapeutics, a biotechnology company leading the field of epitope shielding, is presenting data for its CD52 program during this week’s Annual Meeting of the American Society of Cell & Gene Therapy (ASGCT) in Baltimore. The abstract is titled “Molecular Shielding of CD52 Retains Expression, Anti-Phagocytic Don’t Eat Me Function and Protects from Alemtuzumab-Mediated Depletion.” The study is the first showing that T cells expres...
Back to Newsroom